Depletion of teratoma-forming pluripotent stem cells

• US 9,175,079 B2
• Filed: 01/28/2011
• Issued: 11/03/2015
• Est. Priority Date: 01/29/2010
• Status: Active Grant

• Current Assignee: Board of Trustees of the Leland Stanford Junior University (Stanford Management Co.)
• Original Assignee: Board of Trustees of the Leland Stanford Junior University (Stanford Management Co.)
• Inventors: Tang, Chad, Weissman, Irving L., Drukker, Micha
• Primary Examiner(s): BELYAVSKYI, MICHAIL A
• Application Number:
  US13/575,511
• Publication Number:
  US 20130028909A1
• Time in Patent Office: 1,740 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 16/28 against receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: C12N 5/0081 Purging biological preparations of unwanted cells

Abstract

Compositions and methods are provided for depletion of pluripotent cells. In one embodiment of the invention, methods are provided for depletion of pluripotent cells from a mixed population of differentiated cells and stem cells, to provide a population of cells substantially free of pluripotent stem cells. Monoclonal antibodies useful in depletion and in identification of pluripotent stem cells are also provided.

Claims

1. A method of depleting teratoma-forming pluripotent stem cells from a mixed cell population comprising cells differentiated from the pluripotent stem cells, the method comprising:

contacting a mixed population of cells suspected of comprising pluripotent stem cells with an antibody that specifically binds an H type-1 antigen epitope recognized by monoclonal antibody 8e11; and

depleting from said population those cells that bind to the antibody, to provide a differentiated cell population depleted of teratoma-forming pluripotent stem cells.

2. The method of claim 1, wherein the antibody that specifically binds an H type-1 antigen is monoclonal antibody 8e11.

3. The method of claim 1, further comprising contacting the mixed population of cells suspected of comprising pluripotent stem cells with a cocktail of antibodies specific for CD9, CD30, CD50, CD90, CD200 and H type-1 antigen;

and

depleting from said population those cells that bind to the cocktail of antibodies.

4. The method of claim 1, wherein the contacting is performed in vitro.

5. The method of claim 3, wherein the pluripotent stem cell is one or more of an induced pluripotent stem cell (iPS), embryonic stem cell and embryonic germ cell.

6. The method of claim 1 wherein the depleted population contains less than 1 in 10⁹ teratogenic pluripotent cells.

7. The method of claim 1 wherein said contacting is performed in vivo.

8. The method of claim 7, wherein the pluripotent stem cell is present.